NASDAQ$CCCC

C4 Therapeutics Inc · Q1 2026 earnings

Q1 2026 earnings · · Investor relations

Briefing

C4 Therapeutics Inc Q1 fiscal 2026: $6.2M revenue, $25.1M net loss

for the year ended December 31, 2025, and notes thereto, which are included in the Company’s 2025 Annual Report on Form 10-K that was filed with the SEC on February 26, 2026, or the 2025 Annual Report. increased by a low-single digit percentage. (SEC accession 0001628280-26-033865)

  • Revenue: $6.2M
  • Net loss: $25.1M
  • Diluted EPS: $-0.20
  • Operating income: $-27.8M
  • increased by a low-single digit percentage.

Headline financials

Total Revenue

$6.15M

Previous: $7.24M-15.0%
EPS (adj)

-$0.20

Previous: -$0.37+45.9%
Capital Expenditures

-$64K

No prior period
Net Income

-$25.1M

Previous: -$26.3M+4.5%
Operating Income

-$27.8M

Previous: -$29.2M+4.7%

Revenue & EPS history

C4 Therapeutics · Revenue · Quarterly

$6.15M

Q1 2026-15%vs Q1 2025
Beat estimate in 7 of 13 quarters(54%)
ActualEstimate

Revenue by segment

C4 Therapeutics · $11.1M total across 1 segment · Q3 2023

  • Collaboration agreements
    $11.1M+63.9%

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q1 2026

Historical avgQ1 2026

+1.0%

Avg return

Earnings day

+4.1%

Avg return

5 days after

-2.2%

Avg return

30 days after

38%

9 / 24 earnings

Positive

+24.0%

Q4 2023

Best reaction

-10.0%

Q4 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.0%+13.0%
Q4 2025+0.4%+17.4%+13.9%
Q3 2025-2.0%-10.0%+8.0%
Q1 2025-0.7%-1.4%+21.7%
Q4 2024-1.9%-10.2%-34.0%
Q3 2024+1.4%+10.1%-17.7%
Q1 2024+0.1%-9.1%-31.4%
Q4 2023+24.0%+34.5%+13.4%
Q3 2023-6.0%+21.5%+7.4%
Q2 2023-1.7%-3.1%-33.8%
Q1 2023+4.8%+5.6%+8.0%
Q4 2022-10.0%-11.0%-40.2%
Q3 2022-8.1%-6.4%-11.8%
Q2 2022+16.7%+6.9%-8.7%
Q1 2022-8.1%-19.3%-24.4%
Q4 2021+13.9%+13.9%+24.3%
Q3 2021-4.6%-7.3%-23.6%
Q2 2021+8.0%+5.6%+33.6%
Q1 2020-0.6%+7.4%+20.4%
Q1 2021-0.6%+7.4%+20.4%
Q2 2020+9.6%+7.2%-19.8%
Q3 2019-3.7%+8.3%+8.3%
Q4 2019-3.7%+8.3%+8.3%
Q3 2020-3.7%+8.3%+8.3%
Q1 2019
Q4 2018

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro